Predicate Research Report · generated 2026-08-22 · Print / save as PDF · Save to account
Quidel Corporation — Predicate Candidate Screening
37 FDA 510(k) clearances under this manufacturer; the 50 most recent screened below.
88 daysmedian FDA review time
265 days90th percentile
37clearances measured
| K-number | Device | Applicant | Decided | Review days | Recalls (K-match) |
|---|---|---|---|---|---|
| K231795 | QuickVue COVID-19 Test | Quidel Corporation | 2024-03-22 | 276 | 0 |
| K232286 | Savanna HSV 1+2/VZV Assay, Savanna HSV 1+2/VZV Control Set, | Quidel Corporation | 2023-12-20 | 141 | 0 |
| K233688 | Sofia 2 SARS Antigen+ FIA; Sofia 2 SARS Antigen+ FIA Control | Quidel Corporation | 2023-12-13 | 26 | 0 |
| K230349 | Lyra RSV+hMPV Assay | Quidel Corporation | 2023-03-10 | 29 | 0 |
| DEN220039 | Sofia 2 SARS Antigen+ FIA, Sofia 2 SARS Antigen+ FIA Control | Quidel Corporation | 2023-03-08 | 265 | 0 |
| K230236 | Lyra Influenza A+B Assay | Quidel Corporation | 2023-03-03 | 32 | 0 |
| K211342 | Sofia 2 Campylobacter FIA | Quidel Corporation | 2021-11-23 | 204 | 0 |
| K173496 | Sofia 2 Lyme FIA, Sofia Lyme Control Set | Quidel Corporation | 2018-08-30 | 290 | 0 |
| K181029 | Solana Bordetella Complete Assay | Quidel Corporation | 2018-07-15 | 88 | 1 |
| K173691 | Sofia Lyme FIA, Sofia 2 analyzer, Sofia 2 Installation Pack | Quidel Corporation | 2018-02-28 | 89 | 0 |
| K180288 | QuickVue Influenza A+B | Quidel Corporation | 2018-02-13 | 12 | 0 |
| K173250 | Solana GBS Assay | Quidel Corporation | 2017-12-21 | 72 | 0 |
| K171976 | Sofia Strep A+ FIA, Sofia 2 Analyzer | Quidel Corporation | 2017-12-21 | 174 | 0 |
| K163713 | Sofia Lyme FIA, Sofia Lyme Control Set | Quidel Corporation | 2017-10-20 | 294 | 0 |
| K171974 | Solana RSV+hMPV Assay | Quidel Corporation | 2017-10-16 | 108 | 0 |
| K170491 | Solana C. difficile Assay | Quidel Corporation | 2017-05-11 | 83 | 0 |
| K162438 | Sofia Influenza A+B FIA on Sofia 2 | Quidel Corporation | 2017-04-14 | 226 | 0 |
| K162911 | Sofia RSV FIA on Sofia 2 analyzer | Quidel Corporation | 2017-02-22 | 128 | 0 |
| K162451 | Solana HSV 1+2/VZV Assay | Quidel Corporation | 2016-11-28 | 88 | 0 |
| K162274 | Solana Strep Complete Assay | Quidel Corporation | 2016-10-25 | 74 | 0 |
| K161814 | Solana Influenza A+B Assay | Quidel Corporation | 2016-09-27 | 88 | 0 |
| K161182 | Solana Trichomonas Assay | Quidel Corporation | 2016-08-15 | 110 | 0 |
| K153012 | Sofia Influenza A+B FIA | Quidel Corporation | 2016-01-12 | 90 | 0 |
| K150868 | Solana GAS Assay, Solana instrument | Quidel Corporation | 2015-06-23 | 83 | 0 |
| K143329 | AmpliVue Trichomonas Assay | Quidel Corporation | 2015-03-17 | 117 | 0 |
| K141775 | SOFIA (R) STREP A+ FIA | Quidel Corporation | 2014-12-16 | 168 | 1 |
| K143206 | AmpliVue Bordetella Assay | Quidel Corporation | 2014-12-10 | 33 | 0 |
| K141927 | LYRA PARAINFLUENZA VIRUS ASSAY | Quidel Corporation | 2014-10-09 | 85 | 0 |
| K141931 | LYRA ADENOVIRUS ASSAY | Quidel Corporation | 2014-10-09 | 85 | 0 |
| K141173 | AMPLIVUE GAS ASSAY | Quidel Corporation | 2014-07-24 | 79 | 0 |
| DEN140005 | LYRA DIRECT STREP ASSAY | Quidel Corporation | 2014-04-16 | 22 | 0 |
| K140029 | AMIPLIVUE HSV 1&2 ASSAY | Quidel Corporation | 2014-03-26 | 79 | 0 |
| K133503 | AMPLIVUE GBS ASSAY | Quidel Corporation | 2013-12-20 | 36 | 0 |
| K131599 | QUICK VUE INFLUENZA | Quidel Corporation | 2013-07-05 | 32 | 0 |
| K123793 | SOFIA STREP A FIA | Quidel Corporation | 2013-06-17 | 189 | 0 |
| K123355 | AMPLIVUE C. DIFFICILE ASSAY | Quidel Corporation | 2012-12-13 | 43 | 0 |
| K102175 | RAPIDVUE HCG TEST | Quidel Corporation | 2010-08-25 | 23 | 0 |
Methodology
Recall counts reflect FDA recall records explicitly referencing each K-number; FDA links recalls to K-numbers inconsistently, so 0 means "none found in FDA records," not "never recalled." Data: FDA openFDA, refreshed weekly. Verify decisions of consequence against the primary source. Full candidate set and CSV export: atlasbyauro.com.
Prepared with Atlas
Predicate research, review-time statistics and recall monitoring for 510(k) teams — atlasbyauro.com/fda